Track NeoGenomics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

NeoGenomics, Inc. NEO · Stock Open NeoGenomics, Inc. in new tab

16.02 USD
EPS
-0.24
P/B
2.84
ROE
-3.94
Beta
1.83
Target Price
23.40 USD
NeoGenomics, Inc. logo

NeoGenomics, Inc.

🧾 Earnings Recap – Q1 2026

NeoGenomics shares rose 4.1% following Q1 2026 results, as revenue growth, margin improvement, and NGS expansion topped expectations. Revenue surpassed guidance, with clinical and NGS businesses driving performance and improved profitability.

  • Total Q1 revenue reached $186.7 million, up 11% year-over-year and ahead of previously issued guidance.
  • Adjusted EBITDA was $9 million, increasing 27% over the prior-year period, with a 60 basis point margin improvement.
  • Clinical revenue rose 14% year-over-year to $171 million, fueled by 8% growth in average unit price (AUP) and 6% volume growth.
  • NGS revenue expanded 26% year-over-year, now accounting for one-third of clinical revenue, and growing well ahead of the broader NGS market rate.
  • Recent acquisitions and product launches, including the Pathline integration and PanTracer liquid biopsy, are positioned to sustain above-market growth and share gains in the community oncology segment.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 16, 2027
EPS-0.24
Book Value6.20
Price to Book2.84
Debt/Equity56.10
% Insiders2.099%
Growth
Revenue Growth0.11%
Estimates
Forward P/E55.95
Forward EPS0.31
Target Mean Price23.40

DCF valuation

Model fair value for NeoGenomics, Inc. (NEO)
Result
Sign in to run the valuation for NEO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
10 analysts · consensus Buy · mean target 23.40 USD (low 19.00, high 35.00) · as of 10 Nov 2026
Low 19.00
Mean 23.40
High 35.00
Price 16.02
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

NeoGenomics, Inc. Logo NeoGenomics, Inc. Analysis (NEO)

United States Health Care Official Website Stock

Is NeoGenomics, Inc. a good investment? NeoGenomics, Inc. (NEO) is currently trading at 16.02 USD. Market analysts have a consensus price target of 23.40 USD. This suggests a potential upside from current levels.

Earnings Schedule: NeoGenomics, Inc. is expected to release its next earnings report on Feb. 16, 2027. The market consensus estimate for Forward EPS is 0.31.

Investor FAQ

Does NeoGenomics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is NeoGenomics, Inc.?

NeoGenomics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Feb. 16, 2027. The company currently has a trailing EPS of -0.24.

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Exchange Ticker
NCM (Australia) NEO
Trades
Dividend History paid per year (USD)
Historical Dividends
Year Total Dividends
▸2020
0.40 USD
Dec. 30, 2020 0.4000
Stock Splits
Split Date Split Ratio to 1
Nov. 17, 2000 4:1
April 16, 2003 1:100
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion